Effects of Taurine on Seizures and Growth Hormone Release in Epileptic Patients

Publisher Website
Google Scholar
Abstract
• Oral taurine at doses of 375 to 8,000 mg/day (16 to 150 mg/kg/day) was administered to six patients with mixed seizure disorders refractory to standard anticonvulsant treatment. No improvement in seizure control was observed. During taurine tolerance testing, a substantial rise in plasma growth hormone concentration was noted in four of the six patients. Mean baseline concentrations of 3.0 ± 2.3 and 1.3 ± 0.9 ng/mL were increased to mean peak concentrations of 17.1 ± 2.4 (P <.005) and 20.4 ± 5.1 ng/ mL (P <.025), respectively. Cerebrospinal fluid homovanillic acid (HIV) concentration was also noted to be higher in two of three patients two weeks after initiation of taurine. Initial HVA concentrations of 20.3 and 28.2 ng/mL increased to 37.2 and 54.2 ng/mL, respectively. The possible effect of taurine on central dopaminergic mechanisms is discussed.

This publication has 3 references indexed in Scilit: